Journal Mobile Options
Table of Contents
Vol. 66, No. 6, 2006
Issue release date: November 2006

Hypercalcaemia in Relapsed Medulloblastoma 8 Years Post-Diagnosis; Evidence to Support PTHrP Production by Medulloblastoma Cells

Dharmaraj P. · Ball S. · Johnstone H. · Bailey S. · Clifford S.C. · Hale J. · Cheetham T.D.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: A 19-year-old male presented with symptomatic hypercalcaemia as the first manifestation of relapsed metastatic medulloblastoma. Management at the time of the initial presentation 8 years earlier was with surgical excision and craniospinal radiotherapy. His biochemistry at the time of relapse and studies of medulloblastoma cell lines provide an insight into the pathogenesis of his hypercalcaemia. Methods: Parathyroid hormone-related protein (PTHrP) was measured by immunoradiometric assay in blood, and in conditioned and control media from three medulloblastoma cell lines following 72 h growth. Results: The histology at initial presentation (11 years of age) and at the time of relapse (with bone marrow infiltration and widespread bony metastases) demonstrated medulloblastoma. Ionised calcium concentrations at relapse were 2.89 mmol/l and serum PTHrP levels were increased at the same time (2.7 pmol/l; normal range: 0.7–1.8 pmol/l). There was evidence of PTHrP production by one cell line (MHH-MED-8A) while results for both other lines tested were below the limit of detection. Conclusions: Relapse 8 years after diagnosis is unusual in medulloblastoma and for this relapse to manifest as hypercalcaemia is also very uncommon. Our investigations suggest that the clinical picture was a reflection of PTHrP production by medulloblastoma cells.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Coggeshall J, Merrill W, Hande K, Des Prez R: Implications of hypercalcemia with respect to diagnosis and treatment of lung cancer. Am J Med 1986;80:325.
  2. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF: Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center [see comment]. Cancer 1993;70:1309.

    External Resources

  3. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG: Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia [see comment]. Lancet 1992;339:164.
  4. Nussbaum SR, Gaz RD, Arnold A: Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990;323:1324.
  5. Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T: Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994;79:1322.
  6. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ: What’s new in neuro-oncology? Recent advances in medulloblastoma [Review] [64 refs]. Eur J Paediatr Neurol 2003;7:53.
  7. Jenkin D: Posterior fossa tumors in childhood: radiation treatment. Clin Neurosurg 1983;30:203.
  8. Lindsey J, Lusher M, Anderton J, Bailey S, Gilbertson RJ, Pearson A, Ellison DW, Clifford SC: Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004;25:661.
  9. Fraser WD, Robinson J, Lawton R, Durham B, Gallacher SJ, Boyle IT, Beastall GH, Logue FC: Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein. Clin Chem 1993;39:414.
  10. Mundy GR, Martin TJ: The hypercalcemia of malignancy: pathogenesis and management [Review] [207 refs]. Metabolism 1982;30:1247.

    External Resources

  11. Arisaka O, Obinata K, Yabuta K, Ishimoto K, Sato K: Hypercalcaemia in cerebellar medulloblastoma: pathogenesis of solid tumour-associated hypercalcaemia. Eur J Pediatr 1987;146:434.
  12. Akyuz C, Yalcin B, Kutluk T, Cila A, Buyukpamukcu M: Medulloblastoma with widespread skeletal metastases presenting with hypercalcemia. Med Pediatr Oncol 1999;33:126.
  13. Martin TJ, Atkins D: Biochemical regulators of bone resorption and their significance in cancer. Essays Med Biochem 1979;4:49.
  14. Albright F: Case records of the Massachusetts General Hospital (case 27401). N Engl J Med 1940;225:789.
  15. Simpson EL, Mundy GR, D’Souza SM, Ibbotson KJ, Bockman R, Jacobs JW: Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. N Engl J Med 1983;309:325.
  16. Strewler GJ, Budayr AA, Clark OH, Nissenson RA: Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993;76:1373.
  17. Kukreja SC, Shemerdiak WP, Lad TE, Johnson PA: Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. J Clin Endocrinol Metab 1980;50:167.

    External Resources

  18. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE: Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 1980;303:1377.
  19. Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE: Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest1988;80:596.

    External Resources

  20. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893.
  21. Martin TJ, Suva LJ: Parathyroid hormone-related protein in hypercalcaemia of malignancy [Review] [80 refs]. Clin Endocrinol 1989;30:631.

    External Resources

  22. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Milstone L, Barton DE: Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 1988;85:597.
  23. Shigeno C, Yamamoto I, Kitamura N, Noda T, Lee K, Sone T, Shiomi K, Ohtaka A, Fujii N, Yajima, H: Interaction of human parathyroid hormone-related peptide with parathyroid hormone receptors in clonal rat osteosarcoma cells. J Biol Chem 1988;263:18369.
  24. Yates AJ, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR: Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest 1988;80:932.

    External Resources

  25. Orloff JJ, Wu TL, Stewart AF: Parathyroid hormone-like proteins: biochemical responses and receptor interactions [Review] [136 refs]. Endocr Rev 1989;10:476.
  26. Weir EC, Brines ML, Ikeda K, Burtis WJ, Broadus AE, Robbins RJ: Parathyroid hormone-related peptide gene is expressed in the mammalian central nervous system. Proc Natl Acad Sci USA 1990;87:108.
  27. Yamamoto M, Harm SC, Grasser WA, Thiede MA: Parathyroid hormone-related protein in the rat urinary bladder: a smooth muscle relaxant produced locally in response to mechanical stretch. Proc Natl Acad Sci USA 1992;89:5326.
  28. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ: Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein [see comment]. Science 1996;273:613.
  29. Stewart AF: Clinical practice. Hypercalcemia associated with cancer [Review] [46 refs]. N Engl J Med 2005;352:373.
  30. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996;80:607.

    External Resources

  31. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocana A, Stewart AF: Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1–36) [hPTHrP-(1–36)] versus hPTH-(1–34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003;88:1603.
  32. Rankin W, Grill V, Martin TJ: Parathyroid hormone-related protein and hypercalcemia [Review] [75 refs]. Cancer 1997;80:1564.
  33. Bucht E, Rong H, Pernow Y, Nordqvist AC, Eriksson E, Rankin W, von Schoultz E, Burtis WJ, Granberg B, Falkmer UG, Burton DW, Deftos LJ: Parathyroid hormone-related protein in patients with primary breast cancer and eucalcemia. Cancer Res 1998;58:4113.
  34. Motokura T, Fukumoto S, Matsumoto T, Takahashi S, Fujita A, Yamashita T, Igarashi T, Ogata E: Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. Ann Intern Med 1989;110:484.
  35. Isales C, Carcangiu ML, Stewart AF: Hypercalcemia in breast cancer. Reassessment of the mechanism. Am J Med 1987;82:1143.
  36. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F: Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma [see comment]. Ann Intern Med 1994;120:633.
  37. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003;20:1581.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50